Axogen completes BioCircuit acquisition, adds NerveTape
BioCircuit’s expected revenue contributions were not included in Axogen’s most recently issued full-year 2026 guidance.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Axogen, Inc. (AXGN) completed its acquisition of BioCircuit Technologies, Inc. on October 1, 2026, adding NerveTape, described as the first FDA-cleared sutureless device for peripheral nerve repair. BioCircuit develops and commercializes devices for peripheral nerve repair and neuromodulation.
Axogen expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 revenue and approximately $34 million to 2027 revenue. These expected contributions were not included in Axogen’s most recently issued full-year 2026 guidance of at least 24% revenue growth. Axogen continues to expect gross margin to be at least 73% and to be free cash positive for full-year 2026. BioCircuit also has expertise in biomaterials, precision Nitinol design and manufacturing, and bioelectronics for nerve stimulation and recording. Axogen identifies integration and realization of the acquisition’s anticipated benefits as subject to risks and uncertainties, and cautions that actual results may differ materially from forward-looking statements.
Positive
- Minor point. Forward-looking: it has not happened yet and may not happen.BioCircuit’s 2027 revenue contribution is expected to be approximately $34 million.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Revenue contribution: Approximately $6 million
Revenue contribution: Approximately $34 million
Revenue growth: At least 24%
+1 more
4 metrics
Revenue contribution
Approximately $6 million
BioCircuit; fourth-quarter 2026 expected revenue
Revenue contribution
Approximately $34 million
BioCircuit; 2027 expected revenue
Revenue growth
At least 24%
Axogen’s most recently issued full-year 2026 guidance
Gross margin
At least 73%
Axogen’s full-year 2026 expectation
Key Terms
neuromodulation, Nitinol, transected nerves, gross margin
4 terms
neuromodulation medical
"devices for peripheral nerve repair and neuromodulation"
Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.
Nitinol technical
"precision Nitinol design and manufacturing"
Nitinol is a nickel‑titanium metal alloy known for “shape memory” and spring‑like flexibility: it can return to a preset shape after bending or heating, like a paperclip that snaps back when warmed. Investors track it because those unique properties make it a go‑to material for medical implants, surgical tools and precision devices, so changes in availability, cost, regulation or technical advances can directly affect manufacturers’ product performance, margins and regulatory risk.
transected nerves medical
"repairing transected nerves"
Nerves that have been physically cut or severed, either partially or completely, so the normal electrical signals between the body and the brain or spinal cord are interrupted. This differs from nerve injury caused by pressure, inflammation, or disease: a transection is a mechanical break in the nerve fiber that typically prevents signal transmission until the nerve is surgically repaired or, in some peripheral nerves, regenerates over time under certain biological conditions.
gross margin financial
"gross margin to be at least 73%"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue is BioCircuit expected to add to AXGN?
BioCircuit is expected to contribute approximately $6 million to fourth-quarter 2026 revenue and approximately $34 million to 2027 revenue. Axogen completed the acquisition on October 1, 2026.
Was BioCircuit’s expected revenue included in AXGN’s 2026 guidance?
No. The expected contribution was not included in Axogen’s most recently issued full-year 2026 guidance of at least 24% revenue growth. Axogen also continues to expect gross margin to be at least 73% and to be free cash positive for full-year 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 1, 2026
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of
Incorporation or Organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
(Address of principal executive offices)
(Zip Code)
(386 ) 462-6800
(Registrant's telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On October 1, 2026 , Axogen, Inc. (the “Company”) issued a press release announcing the completion of its previously announced acquisition of BioCircuit Technologies, Inc (the “Acquisition”).
The Company is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a press release announcing its entry into closing of the Acquisition.
The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | ||||
| 99.1 | Press Release, dated October 1, 2026 | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AXOGEN, INC. | ||||||||
| Dated: October 1, 2026 | By: | /s/ Marc Began | ||||||
| Marc Began | ||||||||
| Executive Vice President, General Counsel and Chief Compliance Officer | ||||||||
Exhibit 99.1
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
ALACHUA and TAMPA, FL – October 1, 2026 - Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it has completed its previously announced acquisition of BioCircuit Technologies, Inc. (“BioCircuit”), a privately held medical device company and developer of NerveTape™.
“This is a significant day for Axogen and the surgeons and patients we serve,” said Michael Dale, President and Chief Executive Officer of Axogen. “NerveTape represents a new standard of care as the first sutureless nerve repair option—one that is simpler, faster, and more effective than microsuturing. This innovative technology directly addresses surgeons’ everyday need to repair nerves and aligns perfectly with Axogen’s mission to make the restoration of peripheral nerve function an expected standard of care. It is therefore an ideal fit with our direct sales organization and hospital contracting capabilities, enabling and unlocking NerveTape’s full potential.”
The Company expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 and approximately $34 million to 2027 revenue. This contribution was not included in Axogen’s most recently issued full-year 2026 guidance of at least 24% revenue growth. The Company continues to expect gross margin to be at least 73% and to be free cash positive for the full-year 2026.
About Axogen
Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix®.
About BioCircuit Technologies
BioCircuit Technologies, based in Atlanta, Georgia, develops and commercializes medical devices for peripheral nerve repair and neuromodulation, with expertise in biomaterials, precision Nitinol design and manufacturing, and bioelectronics for nerve stimulation and recording. Its first commercial product, NerveTape™, is the first FDA-cleared sutureless device for repairing transected nerves. BioCircuit has been supported by small business funding from the National Institutes of Health along with private investment from Alsora Capital, GRA Venture Fund, Michael Masters of Masters Capital Management, and other investors. For more information, visit www.biocircuit.com.
Cautionary Statements Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding Axogen’s ability to successfully integrate BioCircuit and realize the anticipated benefits of the acquisition, the expected financial impact of the acquisition and related financial guidance and outlook, including expected revenue, revenue growth, revenue contribution from BioCircuit in the fourth quarter of 2026 and in 2027, gross margin, free cash flow, as well as expectations regarding the commercialization and adoption of NerveTape and the expansion of Axogen’s addressable market. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “upcoming” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties related to the integration of BioCircuit and the realization of the anticipated benefits of the acquisition and the risks and uncertainties inherent in Axogen’s business, including the risks and uncertainties described in the Company’s periodic filings with the SEC. The events and circumstances reflected in the Company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Axogen can be found under the heading “Risk Factors” in Axogen’s periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2025 and in its subsequent quarterly reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Axogen undertakes no obligation to update or revise any forward-looking statements contained herein.
Media Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com.